

Peter S Sever

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7382349/publications.pdf>

Version: 2024-02-01

17
papers

6,997
citations

623734

14
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

14977
citing authors

#	ARTICLE	IF	CITATIONS
1	Nocebo affects after COVID-19 vaccination. <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100273.	5.6	9
2	Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. <i>ESC Heart Failure</i> , 2022, 9, 685-694.	3.1	10
3	William Stanley Peart, MB BS (London) 1943, FRCP 1974, FRS 1969, KBE 1985, clinician, scientist and teacher (Born 31 Mar 1922, Died 14 Mar 2019). <i>Journal of Human Hypertension</i> , 2021, 35, 487-489.	2.2	0
4	Amiloride: A review. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2020, 21, 147032032097589.	1.7	31
5	N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. <i>New England Journal of Medicine</i> , 2020, 383, 2182-2184.	27.0	176
6	Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries. <i>PLoS ONE</i> , 2018, 13, e0198166.	2.5	94
7	Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. <i>Nature Genetics</i> , 2017, 49, 403-415.	21.4	492
8	Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial's Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. <i>Lancet</i> , The, 2017, 389, 2473-2481.	13.7	279
9	Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "omics" in AGEing (HOMAGE) Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	41
10	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. <i>Nature Genetics</i> , 2016, 48, 1151-1161.	21.4	261
11	The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. <i>Nature Genetics</i> , 2016, 48, 1171-1184.	21.4	362
12	Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 136-147.	11.4	99
13	Genetic studies of body mass index yield new insights for obesity biology. <i>Nature</i> , 2015, 518, 197-206.	27.8	3,823
14	Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. <i>Lancet</i> , The, 2015, 386, 2059-2068.	13.7	904
15	Gene-centric Meta-analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood-Pressure-Related Loci. <i>American Journal of Human Genetics</i> , 2014, 94, 349-360.	6.2	158
16	Heart "omics"™ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , 2014, 28, 349.	1.6	24
17	Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. <i>Journal of Hypertension</i> , 2001, 19, 1139-1147.	0.5	234